English

Wilson Therapeutics AB (publ) Year-end Report 2016

Report this content

Good year-end data gives a promising start to 2017

October 1 – December 31, 2016

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 34.1 M (loss: 21.3)
  • Loss per share, before and after dilution, totaled SEK 1.33 (loss: 16.84)
  • At December 31, cash and cash equivalents amounted to SEK 386.6 M (31.4)

January 1 – December 31, 2016

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 115.2 M (loss: 70.5)
  • Loss per share, before and after dilution, totaled SEK 6.84 (loss: 55.53)
  • The board of directors proposes that no dividend be paid for 2016

Significant events during 2016

  • A new share issue raised SEK 39.9 M after issue costs
  • Resolution regarding a 1:10 share split implemented
  • Data from the ongoing Phase 2 trial of WTX101 presented at major medical conferences
  • Wilson Therapeutics listed in the Mid Cap segment on Nasdaq Stockholm, raising SEK 402.7 M after issue costs
  • Management team expanded
  • Clinical Phase 2 study successfully completed

Significant events after the end of the report period

  • Extraordinary general meeting was held in January 2017

“We ended 2016 with great news, reporting the successful completion of our Phase 2 study. We are very encouraged by the data and are now focusing on finalizing the design of the Phase 3 program, which we expect to start in the second half of 2017.”

Jonas Hansson, CEO, Wilson Therapeutics.

 
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is initially being developed as a novel treatment for Wilson Disease and has been evaluated in a Phase 2 clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Visit www.wilsontherapeutics.com for more information.

  For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wtx.se

Wilson Therapeutics AB (publ)
Corp. Reg. No. 556893-0357
Kungsgatan 3
SE-111 43 Stockholm

 
The information in the year-end report is information that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on February 23, 2017.  

Tags:

Wilson Therapeutics Q4 2016

Documents & Links